Acadia Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.
Acadia Pharmaceuticals Inc. was founded in 1993 by Mark R. Brann.
1282 health care and life sciences companies are in the directory, 61 of them in the same 501-1,000 employee range and 28 based in Greater San Diego Area.
Acadia Pharmaceuticals Inc. may be growing as evidenced by a reported revenue increase of 9.3% per year over the last three years. Additionally, the company has expanded its licensing agreement for trofinetide with Neuren Pharmaceuticals in July 2023, indicating a strategic move to enhance its product portfolio. Furthermore, Acadia Pharmaceuticals Inc.'s stock has seen a significant increase, with shares up 47.6% in the year-to-date period, reflecting investor confidence and market performance.
“Acadia advances care for underserved neurological disorders and rare diseases. Since our founding, we have been working at the forefront of healthcare to bring vital solutions to people who need them most.” acadia-pharm.com
Acadia Pharmaceuticals Inc. is a biotechnology company based in Greater San Diego Area, with 501-1,000 employees, founded in 1993. It has raised $811.7 million over 14 rounds and its founder is Mark R. Brann.
501-1,000 employees · apcerls.com
251-500 employees · ahvint.com
1,001-5,000 employees · advancedclinical.com
11-50 employees · 8five8tx.com
11-50 employees · adarx.com
101-250 employees · aveooncology.com
1-10 employees · aionlabs.com
11-50 employees · acllaboratories.com
51-100 employees · aoporphan.com
11-50 employees · abferopharmaceuticals.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.